SCHEMBL7704907

SCHEMBL7704907

Cc1ccc(CN(Cc2ccc3c(c2)NC(=S)C(C)O3)C(=O)OC(C)(C)C)cc1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.38
ALOX15 P16050 2/20 0.38
USP2 O75604 1/20 0.36
GAA P10253 1/20 0.36
BRD4 O60885 1/20 0.36
CREBBP Q92793 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
NCOR2 Q9Y618 1/20 0.36
TSHR P16473 3/20 0.35
PARP1 P09874 2/20 0.34
TP53 P04637 1/20 0.34
POLB P06746 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MAPK1 P28482 1/20 0.33
HTT P42858 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
THRB P10828 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7704945 0.92 HDAC3 (0.44) HSD17B10ALOX15HDAC3HDAC1HDAC2
SCHEMBL7704932 0.91 HDAC3 (0.35) HSD17B10ALOX15HDAC3HDAC1HDAC2
SCHEMBL7711422 0.90 HSD17B10 (0.36) HSD17B10ALOX15USP2HDAC3HDAC1
SCHEMBL6309617 0.90 HDAC1 (0.43) HSD17B10ALOX15HDAC3HDAC1HDAC2
SCHEMBL7708363 0.90 TP53 (0.35) HSD17B10ALOX15GAAHDAC3HDAC1
SCHEMBL7713299 0.89 PARP1 (0.46) HSD17B10ALOX15USP2GAABRD4
SCHEMBL7711220 0.89 HDAC3 (0.34) HDAC3HDAC1HDAC2NCOR2PARP1
SCHEMBL7705060 0.88 CA2 (0.35) HDAC3HDAC1HDAC2NCOR2PARP1
SCHEMBL7710786 0.88 NR1D1 (0.39) HDAC3HDAC1HDAC2NCOR2SMN1; SMN2
SCHEMBL6302990 0.88 PARP1 (0.38) HSD17B10GAABRD4CREBBPHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed